| Trial ID: | L2593 |
| Source ID: | NCT04497792
|
| Associated Drug: |
Empagliflozin 10mg Tab
|
| Title: |
Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions
|
| Acronym: |
SAFARY
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Diabetes Mellitus|Percutaneous Coronary Intervention
|
| Interventions: |
DRUG: Empagliflozin 10Mg Tab|DRUG: hypoglycemic therapy
|
| Outcome Measures: |
Primary: glomerular filtration rate(GFR), The glomerular filtration rate(GFR) will be measured at each visit. GFR more than 60 will be recognized as normal., baseline-24 weeks|HbA1C level, The HbA1C will be measured (in %) at each visit. HbA1C less than 6.1% will be recognized as normal., baseline-24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Research Institute for Complex Problems of Cardiovascular Diseases, Russia
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-11
|
| Completion Date: |
2019-11
|
| Results First Posted: |
|
| Last Update Posted: |
2021-09-22
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04497792
|
